TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34741544
Drug: Nurse-led MBSR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led MBSR therapy + regular diabetes education
Study: 33280397
Drug: Self-applied acupressure
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-applied acupressure in combination with usual treatment
Study: 33331798
Drug: Nutraceutical (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical (combination of soy isoflavone, black cohosh, chasteberry, and evening primrose oil extracts)
Study: 33223141
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of sevoflurane
Study: 33223141
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of sevoflurane
Study: 32232615
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with 106 cfu/mL/kg Lactobacillus acidophilus
Study: 32232615
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (0 cfu/mL/kg Lactobacillus acidophilus)
Study: 32119591
Drug: lyophilized TAK-003
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilized TAK-003 formulation
Study: 32119591
Drug: liquid TAK-003
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid TAK-003 formulation
Study: 35932073
Drug: Nurse-led integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led integrative medicine-based structured education program (4 weeks)
Study: 33423620
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (ET) consisting of aerobic, strengthening and stretching exercises, 2 days/week for 6 weeks in addition to compression therapy (CT)
Study: 33423620
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy (CT) only
Study: 32532356
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of dental pulp stem cells suspension (3.0x10^7 human DPSCs in 30ml saline solution) on days 1, 4, and 7
Study: 32532356
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment for COVID-19
Study: 36448255
Drug: Absorbable polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable polysaccharide hemostatic agent
Study: 36448255
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hemostatic agent)
Study: 38713475
Drug: Therapeutic Drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Drug Monitoring (TDM)
Study: 35544149
Drug: MucoRice-CTB 6
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MucoRice-CTB 6 g
Study: 35544149
Drug: MucoRice-CTB (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: MucoRice-CTB (any dose)
Study: 35544149
Drug: Placebo (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (any dose)
Study: 33403743
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (MPG/phototherapy and PRP-assisted)
Study: 35731529
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 1000 mg on days 1 and 15, 500 mg maintenance at months 12 and 18
Study: 35731529
Drug: Anti-desmoglein 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-desmoglein 3 antibodies (DSG3 Abs) levels
Study: 32024533
Drug: Intra-arterial administration
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of 177Lu-DOTATATE
Study: 32024533
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 177Lu-DOTATATE
Study: 32091613
Drug: Pre‐emptive intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive intrathecal morphine
Study: 32091613
Drug: Post‐operative intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐operative intrathecal morphine
Study: 32091613
Drug: Post‐operative intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post‐operative intrathecal morphine (Group III)
Study: 32091613
Drug: Pre‐emptive intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive intrathecal morphine (Group II)
Study: 32131801
Drug: Biological management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological management of carious lesions and prevention (B + P)
Study: 33362687
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy
Study: 33962762
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate (2400 mg) administered concomitantly with roxadustat (200 mg)
Study: 33962762
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate (1900 mg) administered concomitantly with roxadustat (200 mg)
Study: 33962762
Drug: Roxadustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (200 mg) administered 1 hour before sevelamer carbonate
Study: 33962762
Drug: Roxadustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (200 mg) administered 1 hour after sevelamer carbonate
Study: 33962762
Drug: Roxadustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (200 mg) administered 1 hour before calcium acetate
Study: 33962762
Drug: Roxadustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (200 mg) administered 1 hour after calcium acetate
Study: 33962762
Drug: Roxadustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (200 mg) administered 2 to 3 hours after sevelamer carbonate
Study: 33962762
Drug: Roxadustat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxadustat (200 mg) administered 2 to 3 hours after calcium acetate
Study: 32100576
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (15 minutes, twice a week)
Study: 32112140
Drug: Focal and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal and peripheral laser treatment
Study: 35963005
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ranibizumab with photodynamic therapy)
Study: 33580636
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (cholecalciferol, 50,000 IU/dose)
Study: 32609313
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg once daily for 24 weeks
Study: 32409982
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg CBD
Study: 32409982
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg CBD
Study: 32409982
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg CBD
Study: 34130026
Drug: Non MedDiet
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non MedDiet plus nuts (50 g/day)
Study: 33906126
Drug: Aerosolized hyaluronan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized hyaluronan (HA) - 3 ml inhalation solution containing 0.03% HA, self-administered twice daily
Study: 33271178
Drug: 4 mg/mL
Normalized name: valine 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/mL dexamethasone
Study: 33271178
Drug: 25 mg/mL
Normalized name: hemin 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/mL diclofenac sodium
Study: 35286282
Drug: CEAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEAA supplementation (oral, twice daily for 2 weeks)
Study: 35383071
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac 0.5 mg/kg + IV morphine placebo
Study: 35383071
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine 0.1 mg/kg + IV ketorolac placebo
Study: 32170789
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg lycopene
Study: 32170789
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg lycopene
Study: 32170789
Drug: 80 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/kg lycopene
Study: 32170789
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg lycopene (control group)
Study: 35061634
Drug: Ultrasound-guided CPB
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided CPB with ICPB (CC)
Study: 32474612
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for zone 1 fractures
Study: 32474612
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for zone 1 fractures
Study: 32474612
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for Jones' (zone 2) fractures
Study: 32474612
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for Jones' (zone 2) fractures
Study: 33464986
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment model for high school students with ASD
Study: 34483022
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg QS-21-containing C difficile vaccine
Study: 34483022
Drug: 100 or
Normalized name: Stalevo 100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 or 200 µg unadjuvanted C difficile vaccine formulation
Study: 35169011
Drug: Migraine preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine preventive medication without switching of the overused medication
Study: 35169011
Drug: Migraine preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine preventive medication with switching from the overused medication
Study: 33414442
Drug: BNC210 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC210 (300 mg)
Study: 33414442
Drug: BNC210 (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC210 (2000 mg)
Study: 33414442
Drug: BNC210 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC210 (200 mg)
Study: 33414442
Drug: BNC210 (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNC210 (low dose)
Study: 32129101
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion with supportive care
Study: 33616643
Drug: Avexitide 30
Normalized name: Avexitide
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avexitide 30 mg twice daily
Study: 33616643
Drug: Avexitide 60
Normalized name: Avexitide
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avexitide 60 mg once daily
Study: 32421841
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intramuscular naloxone hydrochloride (PFS)
Study: 35340943
Drug: Macintosh laryngoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macintosh laryngoscope (Group L, N = 60)
Study: 38814736
Drug: Biologics
Normalized name: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics
Study: 33104176
Drug: Plasmalike isotonic
Normalized name: Plasmalyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalike isotonic fluid therapy (140 mmol/L sodium and 5 mmol/L potassium in 5% dextrose)
Study: 33104176
Drug: Moderately hypotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypotonic fluid therapy (80 mmol/L sodium and 20 mmol/L potassium in 5% dextrose)
Study: 33104176
Drug: Plasmalike isotonic
Normalized name: Plasmalyte A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalike isotonic fluid therapy
Study: 33104176
Drug: Moderately hypotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypotonic fluid therapy
Study: 38467912
Drug: Upadacitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (15 mg once daily)
Study: 33053283
Drug: Abatacept (intravenous)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept (intravenous)
Study: 38077624
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated influenza vaccine (QIV)
Study: 34369683
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basic treatment with conventional medication)
Study: 35756420
Drug: Oxycodone (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.02 mg/kg)
Study: 35756420
Drug: Sufentanil (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.02 µg/kg)
Study: 33962962
Drug: Intra-articular sprifermin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sprifermin 100 μg every 6 months (q6mo)
Study: 33962962
Drug: Intra-articular sprifermin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sprifermin 100 μg q6mo
Study: 33349862
Drug: Romidepsin (RMD)
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin (RMD) 0.5 mg/m2, 2 mg/m2, 5 mg/m2 (single dose)
Study: 33349862
Drug: Romidepsin (RMD)
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin (RMD) 5 mg/m2 (multi-dose)
Study: 34749132
Drug: Very-low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-calorie diet (VLCD) with 77 g/day protein for 8 weeks
Study: 34749132
Drug: Very-low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-calorie diet (VLCD) with 52 g/day protein for 8 weeks
Study: 35916669
Drug: Multi-strain probiotic
Normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotic intervention (L. paracasei CNCM I‐1518, L. paracasei CNCM I‐3689, L. rhamnosus CNCM I‐3690, and four yogurt strains)
Study: 32765053
Drug: Inhaled methoxyflurane
Normalized name: methoxyflurane Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methoxyflurane
Study: 34911168
Drug: Monthly feedback
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly feedback reports
Study: 34911168
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alerts and feedback reports
Study: 34204017
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with myofunctional and speech therapy
Study: 34441773
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading protocol using VulkanLoc® abutments after implant emplacement
Study: 35298997
Drug: Daily life
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily life regulation strategies
Study: 33368969
Drug: Endoxifen (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoxifen (8 mg daily)
Study: 32965505
Drug: Prognostic index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic index model for treatment outcome
Study: 32965505
Drug: Prognostic index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic index model for post-treatment participation
Study: 32840767
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of 2.0 g TXA in 10 mL 0.9% NaCl after suturing the joint capsule
Study: 32840767
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 2 g TXA in 200 mL 0.9% NaCl 30 min before the operation
Study: 34705157
Drug: Face-to-face instruction
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face instruction and personalized bowel preparation regimens
Study: 34705157
Drug: Routine bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine bowel preparation regimen and education
Study: 33879260
Drug: Telemedicine-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine-based medication treatment for opioid use disorder (MOUD)
Study: 35947945
Drug: Linear low-intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear low-intensity extracorporeal shockwave therapy (LI-LiESWT) using the PiezoWave2 device with a linear shockwave applicator, administered over 4 treatments in a 4-week period.
Study: 34642416
Drug: Green Therapy
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Therapy room
Study: 32986459
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg methamphetamine
Study: 32986459
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methamphetamine
Study: 32986459
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methamphetamine
Study: 32000474
Drug: Midazolam (medication)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (medication)
Study: 32000474
Drug: Medication (Midazolam)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Midazolam)
Study: 34800178
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks plus axitinib 5 mg twice daily
Study: 36344929
Drug: Polyclonal rabbit
Normalized name: Rabbit
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyclonal rabbit antithymocyte globulin (Grafalon®) 6 mg/kg/day
Study: 35160211
Drug: Craniosacral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniosacral therapy group (CTG)
Study: 34257012
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of low-dose sevoflurane (end-expiratory concentration, 0.4%) through a face mask
Study: 34257012
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (2 mg/kg)
Study: 34257012
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of low-dose sevoflurane
Study: 32163578
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (systolic BP target <120 mmHg)
Study: 32163578
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment (systolic BP target <140 mmHg)
Study: 32846626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LAB and yeast cells
Study: 32482150
Drug: Short-acting beta2
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta2 agonists (SABAs)
Study: 32482150
Drug: Anti-inflammatory reliever
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory reliever therapy (combination of low dose ICS/fast action bronchodilator)
Study: 32868662
Drug: Conventional angiotensin-converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional angiotensin-converting enzyme inhibitors (ACEI)
Study: 36451452
Drug: Esketamine combined
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine combined with sufentanil (Group L)
Study: 36451452
Drug: Esketamine combined
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine combined with sufentanil (Group H, Group M, Group L)
Study: 33951140
Drug: Manually adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually adjusted goal-directed therapy
Study: 32541380
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus 5-hydroxytryptophan (100 mg twice daily)
Study: 33201771
Drug: Eravacycline 1
Normalized name: eravacycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eravacycline 1 mg/kg intravenously every 12 hours
Study: 33201771
Drug: Carbapenem comparators
Normalized name: Carbapenem
DrugBank: Carbapenem (DB18912)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenem comparators (ertapenem 1 g intravenously every 24 hours or meropenem 1 g intravenously every eight hours)
Study: 37979717
Drug: Prophylactic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic heparin
Study: 34598883
Drug: Low-Dose-Rate (LDR)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose-Rate (LDR) brachytherapy
Study: 34598883
Drug: High-Dose-Rate (HDR)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose-Rate (HDR) brachytherapy
Study: 34244280
Drug: Postoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotic prophylaxis
Study: 32466056
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment (80 mg via nasogastric tube)
Study: 32891136
Drug: Dexmedetomidine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.2 μg·kg‐1 combined with remifentanil
Study: 32891136
Drug: Dexmedetomidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.3 μg·kg‐1 combined with remifentanil
Study: 32891136
Drug: Dexmedetomidine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.4 μg·kg‐1 combined with remifentanil